Surrozen, Inc.
NASDAQ:SRZNBiotechnology
Healthcare
$30.67 -4.74%
-$1.14 today
- Market cap
- $229.33M
- Beta
- 0.51
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$31.29
52W Low $8.00High $35.00
Volume 0.09M
Average 0.11M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$30.24M
FY 2025 · Annual
Investing Cash Flow
-$128,000.00
FY 2025 · Annual
Financing Cash Flow
$85.05M
FY 2025 · Annual
+425.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (54.65M) | (36M) | (43.04M) | (63.56M) | (242.03M) |
| Depreciation & Amortization | 2.07M | 1.96M | 1.91M | 1.44M | 537K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.32M | 4.52M | 4.37M | 4.11M | 3.84M |
| Change in Working Capital | (221K) | (8.42M) | (3.93M) | (836K) | 3.15M |
| Accounts Receivables | 0 | (1.98M) | 0 | (502K) | 2.33M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 857K | (2.04M) | (133K) | (228K) | 142K |
| Other Working Capital | (1.08M) | (4.4M) | (3.8M) | (106K) | 678K |
| Other Non-Cash Items | 1.67M | (6.2M) | 325K | 41.22M | 204.26M |
| Operating Cash Flow | (48.81M) | (44.15M) | (40.36M) | (17.63M) | (30.24M) |
| Capital Expenditures | (1.27M) | (728K) | (398K) | (26K) | (128K) |
| Acquisitions (Net) | 0 | (39.04M) | 0 | 0 | 0 |
| Purchases of Investments | (91.74M) | (29.6M) | (28.04M) | 0 | 0 |
| Sales of Investments | 15.3M | 68.64M | 80.17M | 0 | 0 |
| Other Investing Activities | 0 | 39.04M | 0 | 0 | 0 |
| Investing Cash Flow | (77.71M) | 38.31M | 51.72M | (26K) | (128K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 124.22M | 42K | 280K | 16.04M | 85.05M |
| Common Stock Repurchased | 0 | (2.61M) | (4K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 410K | (85K) | 280K | 133K | 0 |
| Financing Cash Flow | 124.63M | (2.57M) | 276K | 16.18M | 85.05M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.89M) | (8.4M) | 11.64M | (1.48M) | 54.68M |
| Free Cash Flow | (50.08M) | (44.87M) | (40.76M) | (17.65M) | (30.37M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$242.0M
+ D&A$537.0K
+ Stock-Based Comp$3.8M
+ Deferred Tax$0
+ Working Capital$3.2M
+ Other Non-Cash$204.3M
= Operating Cash Flow-$30.2M
- Capex-$128.0K
= Free Cash Flow-$30.4M
Analysis
FY2025 free cash flow is -$30.4M. FCF conversion is 12.5% of net income. Operating cash flow was -$30.2M, with capex of -$128.0K. The largest bridge item is Other Non-Cash at $204.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| FWP | FWP filing | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 6, 2026 |
Does SRZN generate free cash flow?
Surrozen, Inc. (SRZN) generated -$30.37M of free cash flow in fiscal 2025.
How much operating cash flow does SRZN produce?
Operating cash flow was -$30.24M, before capital expenditures of $128,000.00.
Continue the stock analysis
Jump to another research area for this company.